<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methohexital: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methohexital: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methohexital: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11337" href="/d/html/11337.html" rel="external">see "Methohexital: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12594" href="/d/html/12594.html" rel="external">see "Methohexital: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709039"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use methohexital only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (eg, pulse oximetry) and cardiac function. Ensure immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F194470"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Brevital Sodium</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F194499"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Barbiturate;</li>
<li>
                        General Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F194474"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d181a5f4-ff4e-4c53-9710-1ef232f62b7c">General anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia:</b>
<b>IV:</b> Usual dosing range: 1 to 1.5 mg/kg for induction; titrate to response and tolerability.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e957755b-7e6a-4c47-abc7-399e245a30c5">Procedural sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation (off-label dose):</b>
<b>IV:</b> Usual dosing range: 0.75 to 1 mg/kg; redose with 0.5 mg/kg every 2 to 5 minutes based on response and tolerability (Bahn 2005).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16f9dccd-d560-4631-83e4-036a7dc3f121">Rapid sequence intubation outside the operating room</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid sequence intubation outside the operating room (off-label use): Note: </b>May cause hypotension; consider alternative agent in patients who are hemodynamically unstable (Stollings 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Usual dosing range: 0.75 to 1.5 mg/kg; redose with 0.5 mg/kg based on response and tolerability (Diaz-Guzman 2010; Farrell 2020; Roberts 2019; Stollings 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6583abf7-75d4-4cf0-8d02-81e4c42a6c4a">Wada test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wada test (off-label use): Intracarotid (off-label route):</b> 3 to 4 mg over 3 seconds; a second dose may be administered at 2 mg over 2 seconds based on response and tolerability (Buchtel 2002; Conradi 2020; Patel 2011).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991280"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988586"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, adjustment may be necessary due to hepatic metabolism. Use with caution.</p></div>
<div class="block doe drugH1Div" id="F194475"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Reduce dose or administer at the low end of the dosage range.</p></div>
<div class="block dop drugH1Div" id="F194487"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12594" href="/d/html/12594.html" rel="external">see "Methohexital: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses must be titrated to effect.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="080b6e42-e6f2-4a56-b258-cad2ee87f704">Induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Induction</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IM: Infants and Children: 5% (50 mg/mL) solution: 6.6 to 10 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Limited data available: Infants, Children, and Adolescents: 1% (10 mg/mL) solution: 1 to 2.5 mg/kg/dose; usual adult dose is 70 mg (ie, 1 mg/kg); if patient is premedicated, dose should be decreased (Björkman 1987; Coté 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Infants and Children: 1% (10 mg/mL) solution or 10% (100 mg/mL) solution: 25 mg/kg/dose; reported maximum dose: 500 mg/dose (Quaynor 1985)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72873dff-bb0a-4144-9fec-01b37666fe14">Preoperative sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Preoperative sedation: </b> Infants and Children:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: 5% (50 mg/mL) solution: 5 to 10 mg/kg/dose (Coté 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: 1% (10 mg/mL) solution or 10% (100 mg/mL) solution: Usual dose: 25 mg/kg/dose; range: 20 to 40 mg/kg/dose; maximum dose: 500 mg/dose (Björkman 1987; Coté 2013; Liu 1980; Pomeranz 2000)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e957755b-7e6a-4c47-abc7-399e245a30c5">Procedural sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Infants and Children: 5% (50 mg/mL) solution: 10 mg/kg/dose (Varner 1985). <b>Note:</b> Some experts do not suggest routine use due to slower onset (Coté 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Limited data available: Infants, Children, and Adolescents: 1% (10 mg/mL) solution: Initial: 0.5 to 1 mg/kg/dose administer immediately prior to procedure; titrate additional doses to achieve level of sedation as needed in increments of 0.5 mg/kg to a maximum total dose: 2 mg/kg total. In the prospective phase of a trial including 20 infants and children (mean age: 26 ± 17 months) undergoing CT scans, a mean dose of 1 ± 0.5 mg/kg/dose was reported (Krauss 2006; Sedik 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Infants and Children: 10% (100 mg/mL) solution: Usual: 25 mg/kg/dose; range: 20 to 35 mg/kg/dose; maximum dose: 500 mg/dose; administer 5 to 15 minutes prior to procedure (Manuli 1993; Pomeranz 2000)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129917"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51129918"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling. However, adjustment may be necessary due to hepatic metabolism. Use with caution.</p></div>
<div class="block adr drugH1Div" id="F194448"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Circulatory depression, circulatory shock, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, salivation</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (injury to nerves adjacent to injection-site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, postanesthetic shivering</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (Whitwam 1978), thrombophlebitis (Whitwam 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hiccups (Whitwam 1978), nausea (Whitwam 1978), vomiting (Whitwam 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (Whitwam 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (Whitwam 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure (Rockoff 1981), tremor (Whitwam 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm (Whitwam 1978), muscle movements (Whitwam 1978)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (Whitwam 1978, Yemen 1991), cough (Whitwam 1978), respiratory depression (Whitwam 1978)</p></div>
<div class="block coi drugH1Div" id="F194462"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to methohexital or any component of the formulation; porphyria (latent or manifest); patients in whom general anesthesia is contraindicated</p></div>
<div class="block war drugH1Div" id="F194445"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving); however, the duration of action is &lt;10 minutes when used for procedural sedation (Bahn 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/tachycardia: May cause temporary hypotension and tachycardia; use with caution in hemodynamically unstable patients (hypotension or shock) or severe hypertension.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Use with caution in patients with severe anemia; respiratory depression may occur leading to further inadequate tissue oxygenation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease including heart failure; consider monitoring cardiac function. Methohexital may enhance preexisting circulatory depression, severe cardiovascular instability, or a shock-like condition; consider using another induction agent in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may prolong or potentiate hypnotic effect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Use with caution in patients with extreme obesity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary disease: May cause respiratory depression; use with caution in patients with pulmonary disease. Use with caution in patients with asthma and chronic obstructive pulmonary disease. Use with extreme caution in patients with ongoing status asthmaticus; hiccups, coughing, laryngospasm, and muscle twitching have occurred impairing ventilation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may prolong or potentiate hypnotic effect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: <b>[US Boxed Warning]: Should only be administered in hospitals or ambulatory care settings with continuous monitoring of respiratory (eg, pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate intubation equipment and trained personnel experienced in handling their use should be immediately available and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the healthcare provider performing the procedure should be present to continuously monitor the patient. </b> Maintenance of a patent airway and adequacy of ventilation must be ensured during use. Laryngospasm is common during induction with all barbiturates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cumulative effect: Repeated dosing or continuous infusions may cause cumulative effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intravenous (IV) administration: Prior to IV administration, ensure patient has adequate IV access; extravasation or intra-arterial injection causes necrosis.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878544"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's or fetus' brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer's labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p></div>
<div class="block foc drugH1Div" id="F194457"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brevital Sodium: 500 mg (1 ea); 2.5 g (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F194441"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323384"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Brevital Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $110.83</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F194501"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F194459"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM administration: Use 5% (50 mg/mL) solution.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Dilute to a maximum concentration of 1% prior to IV use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction of anesthesia: </i>1% (10 mg/mL) solution is administered IV at a rate of ~1 mL/5 seconds or ~2 mg/second.</p>
<p style="text-indent:-2em;margin-left:2em;">Intracarotid (off-label route): Wada test (off-label use): 0.1% (1 mg/mL) solution has been used; administer dose at a rate of 1 mg/second into the internal carotid artery (Buchtel 2002; Patel 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal administration: Use 1% (10 mg/mL) solution; 10% (100 mg/mL) solution has also been used (Pomeranz 2000).</p></div>
<div class="block admp drugH1Div" id="F52613282"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Use 5% solution (50 mg/mL)</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Bolus: For induction, infuse a 1% solution (10 mg/mL) at a rate of ~1 mL/5 seconds (ie, ~2 mg/second, or 12 mL/minute [120 mg/minute] depending upon pump setting)</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Adults: Use a 0.2% solution (2 mg/mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Use a 1% solution (10 mg/mL); a 10% solution (100 mg/mL) has also been given rectally (Björkman 1987; Pomeranz 2000)</p></div>
<div class="block use drugH1Div" id="F194458"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia: </b>Induction of anesthesia prior to the use of other general anesthetic agents; to supplement other anesthetic agents for longer surgical procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation: </b>Short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.</p></div>
<div class="block off-label drugH1Div" id="F25730646"><span class="drugH1">Use: Off-Label: Adult</span><p>Rapid sequence intubation, outside the operating room; Wada test</p></div>
<div class="block mst drugH1Div" id="F194506"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Brevital may be confused with Brevibloc</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299690"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F194450"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Barbiturates may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.  Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.  Management: Monitor INR more closely. Anticoagulant dose increases of 30% to 60%  may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F6743972"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Methohexital crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity may affect brain development. Evaluate benefits and potential risks of fetal exposure to methohexital when duration of surgery is expected to be &gt;3 hours (Olutoye 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Use of methohexital in obstetric anesthesia has been described (Holdcroft 1974; Lee 1966; Verma 1985). However, other agents are more commonly used (ACOG 209 2019; Devroe 2015).</p>
<p style="text-indent:0em;margin-top:2em;">The ACOG recommends that pregnant women should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 775 2019).</p></div>
<div class="block brc drugH1Div" id="F6743975"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Methohexital is present in breast milk (Borgatta 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk concentrations of methohexital were highest ~1 hour following induction of anesthesia in nine women undergoing sterilization ≥1 months postpartum. Methohexital was not measurable in the maternal breast milk of four women 8 to 10 hours after the dose. None of the women had detectable milk or serum concentrations ≥24 hours after the dose (Borgatta 1997).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering methohexital to breastfeeding women. The Academy of Breast Feeding Medicine recommends postponing elective surgery until milk supply and breastfeeding are established. Milk should be expressed ahead of surgery when possible. In general, when the child is healthy and full term, breastfeeding may resume, or milk may be expressed once the mother is awake and in recovery. For children who are at risk for apnea, hypotension, or hypotonia, milk may be saved for later use when the child is at lower risk (ABM [Reece-Stremtan 2017]).</p></div>
<div class="block mop drugH1Div" id="F6744063"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory (eg, pulse oximetry and capnography), cardiovascular (eg, cardiac monitoring, BP, heart rate), CNS status (when used for anesthesia and/or procedures, monitor sedation level).</p></div>
<div class="block pha drugH1Div" id="F194444"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Methohexital is an ultra short-acting IV barbiturate anesthetic. Barbiturates depress the sensory cortex, decrease motor activity, and alter cerebellar function producing drowsiness, sedation, and hypnosis.</p></div>
<div class="block phk drugH1Div" id="F194461"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: Immediate; IM (pediatrics): 2 to 10 minutes; Rectal (pediatrics): 5 to 15 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Single dose:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: 1 to 1.5 hours</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Time to clinical recovery (ie, awake time, sitting and standing steadily, duration of amnesia): 5 to 15 minutes (psychomotor impairment may continue for up to 8 hours) (Barash 2009; Fredman 1994; Korttila 1975)</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal (pediatrics): 45 to 60 minutes (Cote 1994)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism:  Hepatic via demethylation and oxidation</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Rectal: 17%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.6 to 3.9 hours (Ghoneim 1985)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038677"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Brietal sodium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Brevimytal natrium</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Brietal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Brietal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Brietal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Brevital</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Brevimytal hikma | Brevital</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Brietal sodium</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Brevital</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Brietal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Brietal sodium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15829394">
<a name="15829394"></a>Bahn EL and Holt KR, "Procedural Sedation and Analgesia: A Review and New Concepts," <i>Emerg Med Clin North Am</i>, 2005, 23(2):503-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/15829394/pubmed" id="15829394" target="_blank">15829394</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Barash PG, Cullen BF, Stoelting RK, et al, eds, <i>Clinical Anesthesia</i>, 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26046456">
<a name="26046456"></a>Beimer NJ, Buchtel HA, Glynn SM. One center's experience with complications during the Wada test. <i>Epilepsia</i>. 2015;56(8):e110-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/26046456/pubmed" id="26046456" target="_blank">26046456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3426908">
<a name="3426908"></a>Bjorkman S, Gabrielsson J, Quaynor H, et al, “Pharmacokinetics of I.V. and Rectal Methohexitone in Children,” <i>Br J Anaesth</i>, 1987, 59(12):1541-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/3426908/pubmed" id="3426908" target="_blank">3426908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9089420">
<a name="9089420"></a>Borgatta L, Jenny RW, Gruss L, Ong C, Barad D. Clinical significance of methohexital, meperidine, and diazepam in breast milk. <i>J Clin Pharmacol</i>. 1997;37(3):186-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/9089420/pubmed" id="9089420" target="_blank">9089420</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Brevital (methohexital sodium) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12199731">
<a name="12199731"></a>Buchtel HA, Passaro EA, Selwa LM, et al, “Sodium Methohexital (Brevital) as an Anesthetic in the Wada Test,” <i>Epilepsia</i>, 2002, 43(9):1056-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/12199731/pubmed" id="12199731" target="_blank">12199731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33246234">
<a name="33246234"></a>Conradi N, Rosenberg F, Biermann L, et al. Advantages of methohexital over amobarbital in determining hemispheric language and memory lateralization in the Wada test - a retrospective study. <i>Epilepsy Behav</i>. 2020;113:107551. doi:10.1016/j.yebeh.2020.107551<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/33246234/pubmed" id="33246234" target="_blank">33246234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8295806">
<a name="8295806"></a>Coté CJ, “Sedation for the Pediatric Patient,” <i>Pediatr Clin North Am</i>, 1994, 41(1):31-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/8295806/pubmed" id="8295806" target="_blank">8295806</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Coté CJ, Lerman J, Anderson B, eds.<i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Elsevier; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25827280">
<a name="25827280"></a>Devroe S, Van de Velde M, Rex S. General anesthesia for caesarean section. <i>Curr Opin Anaesthesiol</i>. 2015;28(3):240-246. doi: 10.1097/ACO.0000000000000185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/25827280/pubmed" id="25827280" target="_blank">25827280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20045848">
<a name="20045848"></a>Diaz-Guzman E, Mireles-Cabodevila E, Heresi GA, Bauer SR, Arroliga AC. A comparison of methohexital versus etomidate for endotracheal intubation of critically ill patients. <i>Am J Crit Care</i>. 2010;19(1):48-54. doi: 10.4037/ajcc2010562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/20045848/pubmed" id="20045848" target="_blank">20045848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11433853">
<a name="11433853"></a>Dionne RA, Yagiela JA, Moore PA, et al, “Comparing Efficacy and Safety of Four Intravenous Sedation Regimens in Dental Outpatients,” <i>Am Dent Assoc</i>, 2001, 132(6):740-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/11433853/pubmed" id="11433853" target="_blank">11433853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5890378">
<a name="5890378"></a>Elman DS and Denson JS, "Preanesthetic Sedation of Children With Intramuscular Methohexital Sodium," <i>Anesth Analg</i>, 1965, 44(5):494-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/5890378/pubmed" id="5890378" target="_blank">5890378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32739131">
<a name="32739131"></a>Farrell NM, Killius K, Kue R, Langlois BK, Nelson KP, Golenia P. A comparison of etomidate, ketamine, and methohexital in emergency department rapid sequence intubation. <i>J Emerg Med</i>. 2020;59(4):508-514. doi:10.1016/j.jemermed.2020.06.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/32739131/pubmed" id="32739131" target="_blank">32739131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7844577">
<a name="7844577"></a>Folkerts H, “Spontaneous Seizure After Concurrent Use of Methohexital Anesthesia For Electroconvulsive Therapy and Paroxetine: A Case Report,” <i>J Nerv Ment Dis</i>, 1995, 183(2):115-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/7844577/pubmed" id="7844577" target="_blank">7844577</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Published December 14, 2016. Accessed May 26, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2650897">
<a name="2650897"></a>Forbes RB, Murray DJ, Dillman JB, et al, “Pharmacokinetics of Two Percent Rectal Methohexitone in Children,” <i>Can J Anaesth</i>, 1989, 36(2):160-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/2650897/pubmed" id="2650897" target="_blank">2650897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8010457">
<a name="8010457"></a>Fredman B, d'Etienne J, Smith I, Husain MM, White PF. Anesthesia for electroconvulsive therapy: effects of propofol and methohexital on seizure activity and recovery. <i>Anesth Analg</i>. 1994;79(1):75-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/8010457/pubmed" id="8010457" target="_blank">8010457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4036532">
<a name="4036532"></a>Ghoneim MM, Chiang CK, Schoenwald D, et al. The pharmacokinetics of methohexital in young and elderly subjects. <i>Acta Anaesthesiol Scand</i>. 1985;29(5):480-482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/4036532/pubmed" id="4036532" target="_blank">4036532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4834097">
<a name="4834097"></a>Holdcroft A, Robinson MJ, Gordon H, Whitwam JG. Comparison of effect of two induction doses of methohexitone on infants delivered by elective caesarean section. <i>Br Med J</i>. 1974;2(5917):472-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/4834097/pubmed" id="4834097" target="_blank">4834097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9766535">
<a name="9766535"></a>Johns FR, Sandler NA, Buckley MJ, et al, “Comparison of Propofol and Methohexital Continuous Infusion Techniques for Conscious Sedation,” <i>J Oral Maxillofac Surg</i>, 1998, 56(10):1124-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/9766535/pubmed" id="9766535" target="_blank">9766535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1163829">
<a name="1163829"></a>Korttila K, Linnoila M, Ertama P, Häkkinen S. Recovery and simulated driving after intravenous anesthesia with thiopental, methohexital, propanidid, or alphadione. <i>Anesthesiology</i>. 1975;43(3):291-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/1163829/pubmed" id="1163829" target="_blank">1163829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B and Green SM, “Procedural Sedation and Analgesia in Children,” <i>Lancet</i>, 2006, 367(9512):766-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4952997">
<a name="4952997"></a>Lee PF. Anaesthesia for Caesarean section with methohexital. <i>Acta Anaesthesiol Scand Suppl</i>. 1966;23:138-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/4952997/pubmed" id="4952997" target="_blank">4952997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24723301">
<a name="24723301"></a>Lihua P, Su M, Ke W, Ziemann-Gimmel P. Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. <i>Cochrane Database Syst Rev</i>. 2014;(4):CD009763.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/24723301/pubmed" id="24723301" target="_blank">24723301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7425360">
<a name="7425360"></a>Liu LM, Goudsouzian NG, Liu PL. Rectal methohexital premedication in children, a dose-comparison study. <i>Anesthesiology</i>. 1980;53(4):343-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/7425360/pubmed" id="7425360" target="_blank">7425360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19800265">
<a name="19800265"></a>Loddenkemper T, Möddel G, Dinner DS, et al. Language assessment in Wada test: comparison of methohexital and amobarbital. <i>Seizure</i>. 2009;18(9):656-659.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/19800265/pubmed" id="19800265" target="_blank">19800265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8430557">
<a name="8430557"></a>Manuli MA, Davies L. Rectal methohexital for sedation of children during imaging procedures. <i>AJR Am J Roentgenol</i>. 1993;160(3):577-580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/8430557/pubmed" id="8430557" target="_blank">8430557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5936524">
<a name="5936524"></a>Miller JR, Grayson M, and Stoelting VK, "Sedation With Intramuscular Methohexital Sodium for Office and Clinic Ophthalmic Procedures in Children," <i>Am J Ophthalmol</i>, 1966, 62(1):38-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/5936524/pubmed" id="5936524" target="_blank">5936524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888583">
<a name="28888583"></a>Olutoye OA, Baker BW, Belfort MA, Olutoye OO. Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery. <i>Am J Obstet Gynecol</i>. 2018;218(1):98-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/28888583/pubmed" id="28888583" target="_blank">28888583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21325100">
<a name="21325100"></a>Patel A, Wordell C, Szarlej D. Alternatives to sodium amobarbital in the Wada test. <i>Ann Pharmacother</i>. 2011;45(3):395-401. doi:10.1345/aph.1P476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/21325100/pubmed" id="21325100" target="_blank">21325100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10790471">
<a name="10790471"></a>Pomeranz ES, Chudnofsky CR, Deegan TJ, et al, “Rectal Methohexital Sedation for Computed Tomography Imaging of Stable Pediatric Emergency Department Patients,” <i>Pediatrics</i>, 2000, 105(5):1110-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/10790471/pubmed" id="10790471" target="_blank">10790471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4005094">
<a name="4005094"></a>Quaynor H, Corbey M, Björkman S. Rectal induction of anaesthesia in children with methohexitone. Patient acceptability and clinical pharmacokinetics. <i>Br J Anaesth</i>. 1985;57(6):573-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/4005094/pubmed" id="4005094" target="_blank">4005094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Robers.2019">
<a name="Robers.2019"></a>Roberts J. <i>Roberts and Hedges’ Clinical Procedures in Emergency Medicine and Acute Care</i>. 7th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7212335">
<a name="7212335"></a>Rockoff MA, Goudsouzian NG. Seizures induced by methohexital. <i>Anesthesiology</i>. 1981;54(4):333-335. doi:10.1097/00000542-198104000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/7212335/pubmed" id="7212335" target="_blank">7212335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11386953">
<a name="11386953"></a>Sedik H, “Use of Intravenous Methohexital as a Sedative in Pediatric Emergency Departments,” <i>Arch Pediatr Adolesc Med</i>, 2001, 155(6):665-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/11386953/pubmed" id="11386953" target="_blank">11386953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8214358">
<a name="8214358"></a>Schwanda AE, Freyer DR, Sanfilippo DJ, et al, “Brief Unconscious Sedation for Painful Pediatric Oncology Procedures,” <i>Am J Pediatr Hematol Oncol</i>, 1993, 15(4):370-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/8214358/pubmed" id="8214358" target="_blank">8214358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259635">
<a name="24259635"></a>Stollings JL, Diedrich DA, Oyen LJ, Brown DR. Rapid-sequence intubation: a review of the process and considerations when choosing medications. <i>Ann Pharmacother</i>. 2014;48(1):62-76. doi:10.1177/1060028013510488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/24259635/pubmed" id="24259635" target="_blank">24259635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2919762">
<a name="2919762"></a>Urquhart ML and White PF, “Comparison of Sedative Infusions During Regional Anesthesia-Methohexital, Etomidate, and Midazolam,” <i>Anest Analg</i>, 1989, 68(3):249-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/2919762/pubmed" id="2919762" target="_blank">2919762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4003782">
<a name="4003782"></a>Varner PD, Ebert JP, McKay RD, Nail CS, Whitlock TM. Methohexital sedation of children undergoing CT scan. <i>Anesth Analg</i>. 1985;64(6):643-645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/4003782/pubmed" id="4003782" target="_blank">4003782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3160263">
<a name="3160263"></a>Verma R, Ramasubramanian R, Sachar RM. Anesthesia for termination of pregnancy: midazolam compared with methohexital. <i>Anesth Analg</i>. 1985;64(8):792-794.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/3160263/pubmed" id="3160263" target="_blank">3160263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3674498">
<a name="3674498"></a>Wells D, Davies G, and Wagner D, “Accidental Injection of Epidural Methohexital,” <i>Anesthesiology</i>, 1987, 67(5):846-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/3674498/pubmed" id="3674498" target="_blank">3674498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-354663">
<a name="354663"></a>Whitwam JG. Adverse reactions to i.v. induction agents. <i>Br J Anaesth</i>. 1978;50(7):677-687. doi:10.1093/bja/50.7.677<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/354663/pubmed" id="354663" target="_blank">354663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2042766">
<a name="2042766"></a>Yemen TA, Pullerits J, Stillman R, Hershey M. Rectal methohexital causing apnea in two patients with meningomyeloceles. <i>Anesthesiology</i>. 1991;74(6):1139-1141. doi:10.1097/00000542-199106000-00024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methohexital-drug-information/abstract-text/2042766/pubmed" id="2042766" target="_blank">2042766</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9629 Version 300.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
